Tapewire

Nasdaq · USD

ERNA

Ernexa Therapeutics Inc.

Export transactions ↓
Tapewire entity
8278
SEC CIK
0000748592
Parsed reports
266

Last 12 months

Inside the activity.

1 purchase rows · 0 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202500
Dec 202500
Jan 202600
Feb 202610
Mar 202600
Apr 202600
May 202600
Jun 202600
Jul 202600
Aug 202600
Sep 202600
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
November 04, 2016 Filed Nov 8, 2016 00:30 UTC
Wolff AllenCFO and EVP
GrantCommon Stock 26,000 $6.64 $172,640.00
Disclosure

SEC source: 0001493152-16-014599 · form4.xml · nonDerivative · entry 1

Wolff Allen · CIK 0001628529 · CFO and EVP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,910

Read SEC document
November 04, 2016 Filed Nov 8, 2016 00:40 UTC
Miller Dave BrianSVP Marketing
GrantCommon Stock 7,531 $6.64 $50,005.84
Disclosure

SEC source: 0001493152-16-014601 · form4.xml · nonDerivative · entry 1

Miller Dave Brian · CIK 0001673967 · SVP Marketing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,131

Read SEC document
November 04, 2016 Filed Nov 8, 2016 00:29 UTC
Krishnan RamDirector · CEO
GrantCommon Stock 30,000 $6.64 $199,200.00
Disclosure

SEC source: 0001493152-16-014598 · form4.xml · nonDerivative · entry 1

Krishnan Ram · CIK 0001618564 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,900

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.